Another ADHD failure cements Aevi's penny stock status
Aevi Genomic Medicine’s genetic approach to treating ADHD was expected to ascend its lead drug to great heights in the commonly diagnosed neurobehavioral disorder, but this saga has only culminated in another trial failure, forcing the resource-poor company to “reduce the scope” of its operations to preserve capital.
Shares of the Philadelphia-based company $GNMX were obliterated Wednesday afternoon, nosediving nearly 65% after the bell, wading deeper into penny stock territory.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.